# US 2013/0158046 A1 · Biocompatible biodegradable fumagillin analog conjugates

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2013/0158046 A1
- Document ID: US20130158046A1
- Status: Published application
- Kind: A1
- Application number: 13/769,024
- Filed: 2013-02-15
- Published: 2013-06-20
- Earliest claimed: 2007-11-28
- Assignees: Mersana Therapeutics, Inc.
- Inventors: Laura C. Akullian; Russell C. Petter; John J. Kane; Charles E. Hammond; Mao Yin; Aleksandr Yurkovetskiy; Cheri A. Stevenson
- Web page: https://patentgrep.com/patent/US20130158046A1

## CPC

- C07D 303/40: by ester radicals
- A61K 47/59: obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
- A61P 9/00: Drugs for disorders of the cardiovascular system
- A61P 35/00: Antineoplastic agents
- A61P 35/02: specific for leukemia
- C07D 303/18: by etherified hydroxyl radicals
- C07D 303/22: with monohydroxy compounds
- C07D 303/36: with hydrocarbon radicals, substituted by nitrogen atoms (nitro, nitroso radicals C07D303/08)
- C07D 405/14: containing three or more hetero rings
- C07D 487/08: Bridged systems
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

Fumagillin analog polymer conjugates, methods of making fumagillin analog polymer conjugates, compositions comprising a polymer conjugate of a fumagillin analog, and methods for treating cancer, or treating angiogenic diseases comprising administering to a subject in need thereof an effective amount of a polymer conjugate of a fumagillin analog, are described. Also described are novel fumagillin analogs, methods of making fumagillin analogs, compositions comprising at least one fumagillin analog, and methods for treating cancer, or treating angiogenic diseases comprising administering to a subject in need thereof an effective amount of a fumagillin analog.

## Claims

### Claim at position 1

-24. (canceled)

### Claim 25

A compound of the Formula V:
wherein,
X is O, S(═O), optionally substituted CH2, or optionally substituted NH;
q is 0, 1, or 2;
R is (2S,3R)-2-methyl-3-(3-methylbut-2-enyl)oxirane, 2-methylhepta-2,5-diene, (2R,3S)-2-isopentyl-3-methyloxirane, 6-methylhept-2-ene, (Z)-acetaldehyde O-benzyl oxime, C2-heterocyclic-C1-C6 alkyl, C2-heterocyclic-C2-C6 alkenyl, C1-C6 alkyl, C2-C6 alkenyl, C2-heterocyclic-C1-C6-alkenyl-COO—C1-C6 alkyl, C2-heterocyclic-C1-C6 alkyl-COO—C1-C6-alkyl, C1-C6 alkyl=N—O—C1-C6 alkyl-aryl, C(O)C1-C6 alkyl, CN, or halogen;
R8 is selected from the group consisting of VI, VII, VIII, IX, X, XI, XII, and XIIA whose formulas are represented below:
R′—CO2H, optionally substituted —NH2—, or —N cyclic imide, NHC(O) (C1-C6 alkyl)-C(O)R″, R′ is meta or para in relation to the —S— atom; and
R″ is —OH, —O—C1-C6 alkyl, or —NH2 optionally acylated through the carboxyl group of an amino acid;
wherein R9 is H or C(O)R11;
R10 is —NH2, —NHCH(C1-C6 alkyl)-, —NHC(O) (C1-C6 alkyl), N-cyclized imide; —NH acylated through the carboxyl group of an amino acid,
wherein the nitrogen of the amino group of the amino acid is optionally protected, and
R11 is OH, OC1-C6 alkyl, or optionally substituted —NH2;
wherein N12 is H, C1-C6 alkyl, —(C1-C6)—COOH, —(C1-C6)—C(O)O—(C1-C6), —CH2CH2O—R13, —C(O)(C1-C6 alkyl), an amino acid attached through the carboxyl group of the amino acid;
R13 is —H or an amino acid attached through the carboxyl group of the amino acid, wherein the nitrogen of the amino acid is optionally protected, C(O) (C1-C6 alkyl)-COR″;
R″ is —OH, —OC1-C6 alkyl, or —NH2 optionally acylated through the carboxyl group of an amino acid;
[-------] represents an optional methylene bridge (—CH2—) between carbons 2 and 5 of the piperazine moiety; and
Z′ is a bond, —C1-C6 alkyl, —NHC(O)—, or —NHSO2—;
wherein R14 is —H, CO2H, —CO2(C1-C6 alkyl), —C(O)NH—C1-C6 alkyl-OH, wherein the 0 of —C(O)NH—C1-C6 alkyl-OH is optionally acylated with the carboxyl group of an amino acid; optionally substituted —NH, C1-C6-alkyl-NH2, wherein the NH2 is optionally substituted; and
[-------] represents an optional ethylene bridge (—CH2CH2—) between carbons 1 and 4 of the cyclohexane moiety;
Z′ is a bond, —CH2—, —CH2—S—, CH2CH2—, —C(H) (Me)-, NHCH2——NHCH(CH3)—, —NHCH2CH2—;
R15 is H, optionally substituted —NH, —NHC(O) (C1-C6-alkyl), —N cyclized imide optionally containing a heteroatom within the cyclic structure, —NHC(O)CH2OCH2C(O)OH, NHC(O)CH(C1-C6 alkyl)-N cyclized imide, —NHC(O)CH(R″)NHC(O)—(C1-C6 alkyl)-C(O)OH, —NHC(O)—(C1-C6 alkyl)-C(O)OH, —C(O)O(C1-C6 alkyl), —C(O)N(H)(C1-C6 alkyl)-OH, or NO2; and
R″ or —C1-C6 alkyl;
wherein Y′ is C1-C3 alkyl, or NH—C1-C3 alkyl and is attached to positions 1, 2, or 3 of the indole; and
R16 is H, C1-C6 alkyl, —CH2COOH, or —CH2CH2OH, wherein the O of —CH2CH2OH can be optionally acylated with an amino acid;
wherein R″ is —OH, —OC1-C6 alkyl, —NH optionally acylated through the carboxyl group of an amino acid; and
wherein Y″ is C(O)N(CH3)(OCH3), C(O)OCH3, CH2Cl, or NHC(O)CH2Cl.

### Claim at position 3

-31. (canceled)

### Claim 32 (depends on 25)

A composition comprising the compound or pharmaceutically acceptable salt of the compound of claim 25 and a pharmaceutically acceptable carrier.

### Claim at position 5

-35. (canceled)

### Claim 36 (depends on 25)

A composition comprising a compound or pharmaceutically acceptable salt of the compound of claim 25 and a pharmaceutically acceptable carrier.

### Claim 37 (depends on 36)

The composition of claim 36, wherein the pharmaceutically acceptable carrier is suitable for injectable administration and the composition comprises an injectable dosage form.

### Claim 38 (depends on 25)

A method of treating cancer, comprising administering to a subject in need thereof a compound or a pharmaceutically acceptable salt of a compound of claim 25, in an amount effective to treat the cancer.

### Claim 39 (depends on 38)

The method of claim 38, wherein the cancer is selected from the group consisting of anal, astrocytoma, leukemia, lymphoma, head and neck, liver, testicular, cervical, sarcoma, hemangioma, esophageal, eye, laryngeal, mouth, mesothelioma, skin, myeloma, oral, rectal, throat, bladder, breast, uterus, ovary, prostate, lung, colon, pancreas, renal, and gastric.

### Claim 40 (depends on 25)

A method of treating an angiogenic disease, comprising administering to a subject in need thereof a compound or a pharmaceutically acceptable salt of a compound of claim 25, in an amount effective to inhibit angiogenesis.
